A blood sample can tell you a lot. But sometimes the most interesting stuff hides in the middle.
Just above the red blood cells, after centrifugation, lies a thin layer known as the buffy coat. This is where you’ll find peripheral blood mononuclear cells (PBMCs), including lymphocytes and monocytes. These cells can provide incredibly valuable material for studying immune responses, biomarkers and the effects of a treatment.
For researchers, PBMCs are often the starting point for a much bigger question. What is actually happening biologically in response to disease or treatment?
That’s where it gets interesting: what happens to those cells after blood is drawn can influence what information you can obtain from them.
PBMCs are blood cells with a single, round nucleus, made up primarily of lymphocytes and monocytes. They can be used to investigate immune-cell populations, cellular responses and biological changes associated with disease or therapeutic intervention.
That makes PBMCs useful across a wide range of research applications, from immunogenicity and immune profiling to biomarker research, oncology and therapeutic development.
Here's a helpful distinction: the buffy coat isn’t the PBMCs themselves. Instead, it's the thin layer that appears after centrifugation, where these cells are concentrated. Essentially, it’s the initial step in isolating the cells researchers actually want to use.
PBMCs are living cells, so the journey from drawing blood to lab processing matters.
Once blood has been collected, the sample needs to be transported, received and processed within an appropriate timeframe. Delays can affect cell viability and recovery as well as cellular characteristics and function, with potential consequences for downstream analysis.
PBMC processing isn’t simply about collecting the cells and then popping them in a freezer. The entire workflow matters.
Collection, transport, isolation, quality assessment and storage all play a part in determining the quality of the cellular material that eventually reaches the lab for analysis.
There is more than one way to approach PBMC isolation.
At hVIVO, we use density-gradient centrifugation (DGC) with CPT tubes as our standard approach and Ficoll density media separation as an alternative when needed. After isolation, we assess cells for count, viability, and recovery before preparing them for their intended use.
That quality check is incredibly important. A sample might look perfectly fine on paper, but that doesn’t necessarily mean that it will be suitable for every downstream application.
The right processing approach therefore needs to consider what you want to do with the cells afterwards, not just how quickly you can obtain them from the blood.
Once isolated, PBMCs can be analysed immediately, cryopreserved for later use, or prepared for transfer to another laboratory.
Cryopreservation can be particularly useful when clinical studies involve multiple sampling timepoints, or when sample collection and downstream analysis need to happen at different stages. Post-thaw viability and recovery can also be assessed before any samples for further analysis.
PBMCs can provide valuable cellular material for immune profiling, immunogenicity, and biomarker research, helping researchers investigate immune-cell populations, cellular responses, and biological changes associated with treatment.
It’s easy to just think of PBMC isolation as another sample processing step, but it isn’t.
The quality of the material created at this stage can influence what you can do with it later, as well as how useful the resulting data is down the line.
That’s why it’s worth thinking about the process as a whole. Collection, transport, isolation, assessment, storage and analysis are all part of the same clinical story.
The key takeaway? PBMC processing might look like a small step in a much bigger study, but it can have a big influence what happens next. Get the sample right, and you give the science a much better place to start.